Curated News
By: NewsRamp Editorial Staff
November 08, 2026
Blood Pressure Combo May Cut AFib Recurrence After Ablation
TLDR
- Sacubitril/valsartan cut AFib recurrence to 18% versus 28.3% with valsartan alone after ablation, offering a competitive edge in post-procedure care.
- In a 320-patient trial, sacubitril/valsartan reduced AFib recurrence after ablation compared to valsartan alone, despite similar blood pressure reductions.
- This combination therapy may reduce recurring irregular heartbeats after ablation, improving quality of life for older adults with hypertension and AFib.
- Combining sacubitril and valsartan after AFib ablation reduced recurrence by 10 percentage points more than valsartan alone, even with equal blood pressure drops.
Impact - Why it Matters
This news matters because AFib recurrence after ablation is common and can lead to repeat procedures, hospitalizations, and reduced quality of life. The study suggests that the choice of blood pressure medication after ablation could influence outcomes beyond simply lowering blood pressure. If confirmed, this could lead to a simple medication change that helps patients maintain normal heart rhythm longer, reducing the need for additional treatments. For the aging population with hypertension and AFib, these findings offer a potential dual benefit: managing blood pressure while also keeping AFib at bay.
Summary
New preliminary research presented at the American Heart Association’s Scientific Sessions 2026 suggests that for older adults with high blood pressure who undergo ablation for atrial fibrillation (AFib), a combination of two blood pressure medications may help stave off recurring irregular heart rhythms better than one alone. The randomized trial, led by Dr. Wei Zhang of the Shanghai Institute of Hypertension at Ruijin Hospital, followed 320 patients in China (average age 68) for 12 months after their ablation procedure. Half received sacubitril/valsartan (100 mg daily), while the other half received valsartan alone (80 mg daily). Results showed that documented recurrence of AFib or related atrial arrhythmias occurred in 18% of the combination group versus 28.3% in the valsartan-only group. Notably, blood pressure reductions were similar between groups—about 10 mm Hg drop in systolic pressure—suggesting the benefit may not be solely due to blood pressure lowering. “Our findings reinforce the idea that treating AFib does not end with the ablation procedure,” Zhang said, adding that the type of blood pressure medication may matter as much as the degree of reduction.
The study, which was supported by grants from the National Natural Science Foundation of China and other Chinese research programs, has limitations: it was open-label, and heart rhythm monitoring was intermittent. Still, the findings point to a potential new strategy for managing AFib after ablation. As Zhang noted, “AFib is a complex condition, and successful long-term management requires both effective rhythm treatment and careful management of underlying cardiovascular risk factors, particularly hypertension.” The American Heart Association, which hosted the meeting, emphasizes that these results are preliminary until published in a peer-reviewed journal. The association also notes that it receives most of its revenue from non-corporate sources and has strict policies to prevent donations from influencing its science.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, Blood Pressure Combo May Cut AFib Recurrence After Ablation
